January 2024 in “Advanced Science” In this study, researchers used a chemical cocktail and hydrogel microspheres to successfully guide fibroblasts into dermal papilla cells, promoting wound healing and in situ hair follicle regeneration while reducing scar formation, in both in vitro and in vivo experiments.
January 2021 in “Journal of Cancer Therapy” This study described the safety profile of tyrosine kinase inhibitors in treating various solid tumors, finding that the observed toxicities were consistent with existing literature.
July 2025 in “The Journal of Dermatology” This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.
December 2023 in “Journal of Ayub Medical College Abbottabad” In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.
January 2024 in “American journal of clinical dermatology” This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.